Since our establishment in 1968, Dongkook Pharmaceutical has been guided by the corporate philosophy of “Creation, Unity, and Trust", striving for the pursuit of life respect and healthy national livelihood. Over the past 50 years, we have put a great effort for each field inside the company to lay the foundation for leaping into a first-class company. We have been recognized by domestic and foreign authorities for its quality of finished products. We also have acquired Certificate of Suitability (CEP) for Teicoplanin API from EDQM (European Directorate for the Quality of Medicines). Currently, we have developed and exported various pharmaceutical products (FDF, API) to 40 countries worldwide, including the EU, Japan, the Middle East, and Central and South America. We continue to engage in sustained marketing activities targeting global markets.
Furthermore, by developing new products and exploring growth opportunities in various business portfolios such as OTC, ETC, and healthcare products, we have expanded our platform for sustainable growth.
Year of Establishment:
1968
Total Assets(USD):
500,000 to 99,999,999
Total Number of Staff:
500-1000
Main Competitive Advantages:
Experienced R&D Staff,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted
Other Competitive Advantages:
Patents and Copyrights:
Business Type:
Manufacturer
R&D capacity:
Own Brand
Annual Turnover(USD):
500,000 to 99,999,999
Main Sales Markets:
Central/South America,Eastern Europe,Asia,Middle East
Other Competitive Advantages:
Patents and Copyrights:
Audited Supplier
Pharma Sources Insight January 2025
